Condition: Gastric Cancer · Gastrointestinal Cancer · HER2 Gene Mutation · Sponsor: Fox Chase Cancer Center
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gastro-esophageal cancer that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+) and any other gastrointestinal cancer with HER2 expression with IHC3+. Patients must have progressed or been intolerant of at least one prior line of chemotherapy + HER2 directed therapy.
This description comes directly from the study's public registry record.
Namrata Vijavergia, MD · 215-214-1676 · Namrata.Vijayvergia@fccc.edu
Tanu Singh · 215-214-1439 · tanu.singh@fccc.edu
Always discuss trial participation with your own doctor first.
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05274048